Publication of Dicot's report for the third quarter will be brought forward to November 1, 2022. Previously announced date for publication was November 15, 2022.
The reason why the company brings forward the financial report is that the financial statements will be ready faster than expected and that the board therefore sees no reason to delay publication.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.